Global AI In Laboratory Solution Market Trends and Insights
Rising Need for AI-Guided High-Throughput Experimentation
AI-guided high-throughput experimentation is moving from a specialist capability into broader pharmaceutical, materials, and genomics laboratory workflows. Automated platforms can run AI-designed experiment queues faster than schedules prepared manually by research teams. This allows laboratories to assess more candidate conditions without a matching increase in laboratory staffing. A 2026 Scientific Reports study found that self-correcting multi-agent AI systems reduced numerical errors by more than 85% in complex synthesis tasks and achieved an F1-score above 0.89 in multi-plate synthesis benchmarks. These results support the use of AI systems in laboratory settings where researchers need more reliable handling of complex experimental steps. The AI in laboratory solution market is also benefiting as laboratory procurement moves toward connected packages that combine instruments, data platforms, and workflow software.Laboratory Workforce Shortages and Analyst Productivity Pressure
Laboratory workforce shortages are changing the business case for AI-enabled laboratory systems. Many laboratories now consider productivity support a primary reason to adopt AI tools, rather than treating it only as a quality improvement measure. Aging workforces in Germany, Japan, and the United States are limiting the availability of experienced laboratory scientists. At the same time, omics research and multi-parameter assays are creating greater demand for people who can interpret complex datasets. Smaller contract research organizations and academic core facilities often face the greatest workload pressure because they have fewer specialized analysts. This is increasing their interest in AI systems that can structure data, support analysis, and reduce repetitive review work.GxP Validation Burden for AI-Enabled Workflows
Validation requirements remain a major constraint for AI-enabled workflows in regulated pharmaceutical and biotechnology laboratories. Laboratories using AI for GxP-related activities must demonstrate that data, models, decisions, and review records can be traced and reconstructed. The FDA finalized its Computer Software Assurance guidance in September 2025 and updated it in February 2026. The guidance uses a risk-based framework that focuses testing on functions that affect patient safety or product quality. This can simplify validation for lower-risk software functions, but batch release, audit trail, and quality-related workflows still require extensive evidence. The AI in laboratory solution market, therefore, favors vendors that can provide version control, audit trails, human review records, and clear documentation for AI-supported decisions.Other drivers and restraints analyzed in the detailed report include:
- Multi-Omics and High-Dimensional Data Complexity
- Closed-Loop Automation Across Instruments, LIMS, and ELN
- Legacy LIMS, LIS, and Instrument Integration Debt
Segment Analysis
Software and Systems held 64.41% of the AI in laboratory solution market share in 2025. This segment includes LIMS platforms, electronic laboratory notebooks, AI analytics tools, and laboratory workflow orchestration systems. Software captures recurring subscription revenue and supports long-term customer relationships. It also gains value as laboratories use more AI capabilities on the same data environment. Hardware Equipment accounted for the remaining share of revenue. This category includes AI-enabled laboratory instruments, connected sensors, environmental monitoring equipment, and automation platforms with embedded AI functions.Software and Systems is projected to grow at a 13.27% CAGR through 2031. The AI in laboratory solution market size for this segment is supported by laboratories replacing older informatics tools with AI-enabled platforms. Benchling introduced Benchling Inference in May 2026 through a partnership with Baseten to provide scientific AI models and multi-cloud GPU capacity inside its research and development platform. Instrument vendors are also facing greater demand for real-time, machine-readable data outputs that can connect to leading software platforms. Hardware vendors without certified integrations may face weaker positions in procurement decisions. Software platforms are becoming the operational system of record for laboratory data, workflows, and AI-assisted decisions
Predictive analytics and forecasting held 35.16% share of the AI in laboratory solution market size in 2025. Laboratories use predictive models for stability-study monitoring, instrument maintenance, quality monitoring, and planning activities. These uses align with established laboratory processes and generally require less change in scientist behavior. Anomaly detection and review-by-exception tools also represent an important capability area. They allow systems to identify unusual results while retaining human confirmation for final review.
Generative AI copilots and natural language assistance are forecast to grow at a 16.57% CAGR between 2026 and 2031. Vendors are embedding large language model interfaces into LIMS and electronic laboratory notebook platforms. Benchling launched AI Connectors in April 2026 to allow researchers to access scientific records through external AI tools and natural language queries.
The platform supports more than 1,300 companies, including Merck, Moderna, and Sanofi. Workflow automation, semantic search, and quality-signal detection are also gaining importance as laboratories move away from isolated AI tools. Integrated platforms are increasingly replacing separate single-function products.
Complete Report Scope:
- By Solution Type
- Hardware Equipment
- Software and Systems
- By AI Capability
- Predictive Analytics and Forecasting
- Anomaly Detection and Review by Exception
- Generative AI Copilots and Natural Language Assistance
- Intelligent Workflow Automation and Orchestration
- Knowledge Retrieval and Semantic Search
- Quality Signal Detection and Risk Scoring
- Others
- By Deployment
- On-Premise
- Private Cloud and Single-Tenant
- Public Cloud and Multi-Tenant SaaS
- Hybrid
- By End User
- Pharmaceutical and Biotechnology Labs
- CROs and CDMOs
- Clinical Diagnostics and Molecular Labs
- Biobanks and Genomics Labs
- Academic and Translational Research Labs
- Other End Users
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America held 46.38% of the global AI in laboratory solution market share in 2025. The region benefits from a high concentration of pharmaceutical research spending, biotechnology companies, research institutions, and laboratory instrument providers. The United States accounted for most regional revenue because of its large pharmaceutical and biotechnology base. NIH-funded research programs also support the adoption of advanced laboratory data systems. Canada and Mexico are contributing to demand as contract research and manufacturing capacity develop across the North American supply chain.Asia-Pacific is projected to grow at the fastest regional CAGR of 15.28% through 2031. China’s life sciences investment programs and expanding contract research sector are supporting demand for AI-enabled LIMS platforms and multi-omics analytics. Japan combines laboratory automation capabilities with a strong industrial robotics base. MGI Tech and the Shanghai AI Laboratory introduced ProtoPilot and BioLab Bench in July 2026, supporting the use of multi-agent AI systems in life sciences laboratory settings. India is becoming an important regional contributor through investment in genomic diagnostics and related laboratory services. Asia-Pacific is therefore expanding from a customer base for laboratory AI systems into a region that also produces laboratory AI technologies.
Europe holds a significant position in the AI in laboratory solution market because of its major pharmaceutical manufacturing centers in Germany, the United Kingdom, France, and Switzerland. Regional procurement increasingly favors platforms that support data integrity, auditability, and AI governance requirements. The Middle East and Africa remain early-stage markets, with adoption focused on government reference laboratories, research centers, and multinational pharmaceutical sites. Gulf Cooperation Council healthcare digitization programs are supporting demand for clinical laboratory software and connected diagnostics. South America is led by Brazil, where pharmaceutical manufacturing, research universities, and laboratory networks support technology adoption. Both regions are expected to develop further as cloud infrastructure expands and laboratory AI regulations become clearer.
List of Companies Covered in this Report:
- Agilent Technologies
- AIFORIA TECHNOLOGIES OYJ
- Benchling, Inc.
- Bio-Rad Laboratories
- Clinisys
- CloudLIMS
- Danaher
- Dassault Systèmes SE
- Dotmatics, Inc.
- eLabNext
- Illumina
- L7 Informatics, Inc.
- Labguru
- LabVantage Solutions, Inc.
- LabWare
- PathAI, Inc.
- QBench
- QIAGEN
- Revvity, Inc.
- Sapio Sciences LLC
- Scispot
- Siemens Healthineers
- STARLIMS Corporation
- Thermo Fisher Scientific
- Waters Corporation
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Agilent Technologies, Inc.
- AIFORIA TECHNOLOGIES OYJ
- Benchling, Inc.
- Bio-Rad Laboratories, Inc.
- Clinisys
- CloudLIMS
- Danaher Corporation
- Dassault Systèmes SE
- Dotmatics, Inc.
- eLabNext
- Illumina, Inc.
- L7 Informatics, Inc.
- Labguru
- LabVantage Solutions, Inc.
- LabWare
- PathAI, Inc.
- QBench
- QIAGEN N.V.
- Revvity, Inc.
- Sapio Sciences LLC
- Scispot
- Siemens Healthineers AG
- STARLIMS Corporation
- Thermo Fisher Scientific Inc.
- Waters Corporation

